--- title: "Cocrystal Pharma, Inc. (COCP.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/COCP.US.md" symbol: "COCP.US" name: "Cocrystal Pharma, Inc." industry: "Pharmaceuticals" datetime: "2026-05-21T11:53:21.259Z" locales: - [en](https://longbridge.com/en/quote/COCP.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/COCP.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/COCP.US.md) --- # Cocrystal Pharma, Inc. (COCP.US) ## Company Overview Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. | Item | Detail | |------|--------| | Industry | Pharmaceuticals | | Exchange | US Market | | Website | [www.cocrystalpharma.com](https://www.cocrystalpharma.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: D > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-21T04:30:18.000Z **Overall: D (0.70)** **Industry**: Pharmaceuticals | Metric | Value | |--------|-------| | Industry Ranking | 160 / 190 | | Industry Median | C | | Industry Average | C | - **Style**: Blend - Stocks in which the company has both growth and mature businesses. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: D #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 0.00% | | | Net Profit YoY | 44.29% | | | P/B Ratio | 3.72 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 15302192.49 | | | Revenue | 225000.00 | | #### Multi Score Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -154.62% | E | | Profit Margin | -3924.00% | E | | Gross Margin | -509.33% | E | | Revenue YoY | 0.00% | D | | Net Profit YoY | 44.29% | B | | Total Assets YoY | -30.33% | E | | Net Assets YoY | -43.65% | E | | Cash Flow Margin | 86.00% | C | | OCF YoY | 0.00% | D | | Turnover | 0.02 | E | | Gearing Ratio | 44.57% | C | ```chart-data:radar { "title": "Longbridge Financial Score - Cocrystal Pharma, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "0.00%", "rating": "" }, { "name": "Net Profit YoY", "value": "44.29%", "rating": "" }, { "name": "P/B Ratio", "value": "3.72", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "15302192.49", "rating": "" }, { "name": "Revenue", "value": "225000.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "D", "indicators": [ { "name": "ROE", "value": "-154.62%", "rating": "E" }, { "name": "Profit Margin", "value": "-3924.00%", "rating": "E" }, { "name": "Gross Margin", "value": "-509.33%", "rating": "E" }, { "name": "Revenue YoY", "value": "0.00%", "rating": "D" }, { "name": "Net Profit YoY", "value": "44.29%", "rating": "B" }, { "name": "Total Assets YoY", "value": "-30.33%", "rating": "E" }, { "name": "Net Assets YoY", "value": "-43.65%", "rating": "E" }, { "name": "Cash Flow Margin", "value": "86.00%", "rating": "C" }, { "name": "OCF YoY", "value": "0.00%", "rating": "D" }, { "name": "Turnover", "value": "0.02", "rating": "E" }, { "name": "Gearing Ratio", "value": "44.57%", "rating": "C" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -1.73 | 126/190 | - | - | - | | PB | 3.72 | 129/190 | 2.96 | 2.24 | 1.85 | | PS (TTM) | 68.01 | 143/190 | - | - | - | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Cormedix (CRMD.US) | A | A | B | C | B | A | | 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B | | 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B | | 04 | Roche (RHHBY.US) | A | B | B | D | B | B | | 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B | ## Institutional View ### Analyst Rating Distribution > As of 2026-04-07T04:00:00.000Z Total Analysts: **3** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 2 | 67% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 1.11 | | Highest Target | 10.00 | | Lowest Target | 6.00 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/COCP.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/COCP.US/norm.md) - [Related News](https://longbridge.com/en/quote/COCP.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/COCP.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**